Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 38 entries
Sorted by: Best Match Show Resources per page
The impact of undergraduate research and student characteristics on student success metrics at an urban, minority serving, commuter, public institution

Minority STEM

Brown P, Cumming T, Mengeling M.
GSID: FY_uke8NnukJ
SI Baron, P Brown, T Cumming, M Mengeling - 2020 - academicworks.cuny.edu

… longitudinally, at an urban, public, minority and Hispanic serving, commuter college. … full- or part-time status, were STEM or non-STEM majors, or participated in single or multiple …

Cite
Baron, S. I., Brown, P., Cumming, T., & Mengeling, M. (2020). The impact of undergraduate research and student characteristics on student success metrics at an urban, minority serving, commuter, public institution.
Baron, Sheila I., et al. "The impact of undergraduate research and student characteristics on student success metrics at an urban, minority serving, commuter, public institution." (2020).
Copy Download .nbib Format: MLA
Collaborative reflection at work: supporting informal learning at a healthcare workplace

informal learning

Prilla M, Degeling M, Herrmann T.
GSID: 1Sn8o7N1NRcJ
M Prilla, M Degeling, T Herrmann - Proceedings of the 17th ACM …, 2012 - dl.acm.org

… The triad of past experience, reassessment and learning for the future thus makes reflection a unique process of learning and knowledge … Other authors propose digital portfolios for learners, including learning material and personal notes to reflect about...

Cite
Prilla, M., Degeling, M., & Herrmann, T. (2012, October). Collaborative reflection at work: supporting informal learning at a healthcare workplace. In Proceedings of the 17th ACM international conference on Supporting group work (pp. 55-64).
Prilla, Michael, Martin Degeling, and Thomas Herrmann. "Collaborative reflection at work: supporting informal learning at a healthcare workplace." Proceedings of the 17th ACM international conference on Supporting group work. 2012.
Copy Download .nbib Format: MLA
The Veterans Choice Act: A Qualitative Examination of Rapid Policy Implementation in the Department of Veterans Affairs.

Medical care

Mattocks KM, Mengeling M, Sadler A, Baldor R, Bastian L.
PMID: 28146037
Med Care. 2017 Jul;55:S71-S75. doi: 10.1097/MLR.0000000000000667.

BACKGROUND: Congress enacted the Veterans Access, Choice, and Accountability Act of 2014 [Veterans Choice Act (VCA)] to improve access to timely, high-quality health care for Veterans. Although Congress mandated that VCA must begin within 90 days of passage of...

Cite
Mattocks KM, Mengeling M, Sadler A, et al. The Veterans Choice Act: A Qualitative Examination of Rapid Policy Implementation in the Department of Veterans Affairs. Med Care. 2017;55:S71-S75doi: 10.1097/MLR.0000000000000667.
Mattocks, K. M., Mengeling, M., Sadler, A., Baldor, R., & Bastian, L. (2017). The Veterans Choice Act: A Qualitative Examination of Rapid Policy Implementation in the Department of Veterans Affairs. Medical care, 55S71-S75. https://doi.org/10.1097/MLR.0000000000000667
Mattocks, Kristin M, et al. "The Veterans Choice Act: A Qualitative Examination of Rapid Policy Implementation in the Department of Veterans Affairs." Medical care vol. 55 (2017): S71-S75. doi: https://doi.org/10.1097/MLR.0000000000000667
Mattocks KM, Mengeling M, Sadler A, Baldor R, Bastian L. The Veterans Choice Act: A Qualitative Examination of Rapid Policy Implementation in the Department of Veterans Affairs. Med Care. 2017 Jul;55:S71-S75. doi: 10.1097/MLR.0000000000000667. PMID: 28146037.
Copy Download .nbib Format: NLM
Identification of Hog Cholera Viral Antigen by Immunofluorescence. Application as a Diagnostic and Assay Method.

Canadian journal of comparative medicine and veterinary science

Mengeling WL, Pirtle EC, Torrey JP.
PMID: 17649467
Can J Comp Med Vet Sci. 1963 Oct;27(10):249-52.

In the absence of detectable cytologic changes in hog cholera virus-infected tissue culture cells, hog cholera viral antigen was readily detected by immunofluorescence. The ability to detect hog cholera viral antigen by this method allowed for determination of infectivity...

Cite
Mengeling WL, Pirtle EC, Torrey JP. Identification of Hog Cholera Viral Antigen by Immunofluorescence. Application as a Diagnostic and Assay Method. Can J Comp Med Vet Sci. 1963;27(10):249-52
Mengeling, W. L., Pirtle, E. C., & Torrey, J. P. (1963). Identification of Hog Cholera Viral Antigen by Immunofluorescence. Application as a Diagnostic and Assay Method. Canadian journal of comparative medicine and veterinary science, 27(10), 249-52.
Mengeling, W L, et al. "Identification of Hog Cholera Viral Antigen by Immunofluorescence. Application as a Diagnostic and Assay Method." Canadian journal of comparative medicine and veterinary science vol. 27,10 (1963): 249-52.
Mengeling WL, Pirtle EC, Torrey JP. Identification of Hog Cholera Viral Antigen by Immunofluorescence. Application as a Diagnostic and Assay Method. Can J Comp Med Vet Sci. 1963 Oct;27(10):249-52. PMID: 17649467; PMCID: PMC1583710.
Copy Download .nbib Format: NLM
The bioluminescent Listeria monocytogenes strain Xen32 is defective in flagella expression and highly attenuated in orally infected BALB/cJ mice.

Gut pathogens

Bergmann S, Rohde M, Schughart K, Lengeling A.
PMID: 23856386
Gut Pathog. 2013 Jul 15;5(1):19. doi: 10.1186/1757-4749-5-19.

BACKGROUND: In vivo bioluminescence imaging (BLI) is a powerful method for the analysis of host-pathogen interactions in small animal models. The commercially available bioluminescent Listeria monocytogenes strain Xen32 is commonly used to analyse immune functions in knockout mice and...

Cite
Bergmann S, Rohde M, Schughart K, et al. The bioluminescent Listeria monocytogenes strain Xen32 is defective in flagella expression and highly attenuated in orally infected BALB/cJ mice. Gut Pathog. 2013;5(1):19doi: 10.1186/1757-4749-5-19.
Bergmann, S., Rohde, M., Schughart, K., & Lengeling, A. (2013). The bioluminescent Listeria monocytogenes strain Xen32 is defective in flagella expression and highly attenuated in orally infected BALB/cJ mice. Gut pathogens, 5(1), 19. https://doi.org/10.1186/1757-4749-5-19
Bergmann, Silke, et al. "The bioluminescent Listeria monocytogenes strain Xen32 is defective in flagella expression and highly attenuated in orally infected BALB/cJ mice." Gut pathogens vol. 5,1 (2013): 19. doi: https://doi.org/10.1186/1757-4749-5-19
Bergmann S, Rohde M, Schughart K, Lengeling A. The bioluminescent Listeria monocytogenes strain Xen32 is defective in flagella expression and highly attenuated in orally infected BALB/cJ mice. Gut Pathog. 2013 Jul 15;5(1):19. doi: 10.1186/1757-4749-5-19. PMID: 23856386; PMCID: PMC3720536.
Copy Download .nbib Format: NLM
Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform.

Current chemical genomics and translational medicine

Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ.
PMID: 24772387
Curr Chem Genom Transl Med. 2014 Mar 07;8:36-46. doi: 10.2174/2213988501408010036. eCollection 2014.

To adapt the use of GH3.TRE-Luc reporter gene cell line for a quantitative high-throughput screening (qHTS) platform, we miniaturized the reporter gene assay to a 1536-well plate format. 1280 chemicals from the Library of Pharmacologically Active Compounds (LOPAC) and...

Cite
Freitas J, Miller N, Mengeling BJ, et al. Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform. Curr Chem Genom Transl Med. 2014;8:36-46doi: 10.2174/2213988501408010036.
Freitas, J., Miller, N., Mengeling, B. J., Xia, M., Huang, R., Houck, K., Rietjens, I. M., Furlow, J. D., & Murk, A. J. (2014). Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform. Current chemical genomics and translational medicine, 836-46. https://doi.org/10.2174/2213988501408010036
Freitas, Jaime, et al. "Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform." Current chemical genomics and translational medicine vol. 8 (2014): 36-46. doi: https://doi.org/10.2174/2213988501408010036
Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, Rietjens IM, Furlow JD, Murk AJ. Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform. Curr Chem Genom Transl Med. 2014 Mar 07;8:36-46. doi: 10.2174/2213988501408010036. eCollection 2014. PMID: 24772387; PMCID: PMC3999704.
Copy Download .nbib Format: NLM
Adjuvant Hysterectomy for Cervical Cancer Patients Treated with Chemoradiation Therapy: A Systematic Review on the Pathology-Proven Residual Disease Rate.

Cancers

van Kol K, Ebisch R, Piek J, Beugeling M, Vergeldt T, Bekkers R.
PMID: 34944810
Cancers (Basel). 2021 Dec 08;13(24). doi: 10.3390/cancers13246190.

OBJECTIVE: To determine the incidence of pathology-proven residual disease in adjuvant hysterectomy specimens in patients with cervical cancer, treated with chemoradiation therapy. Secondly, to assess a possible association for pathology-proven residual disease regarding the time between chemoradiation therapy and...

Cite
van Kol K, Ebisch R, Piek J, et al. Adjuvant Hysterectomy for Cervical Cancer Patients Treated with Chemoradiation Therapy: A Systematic Review on the Pathology-Proven Residual Disease Rate. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246190.
van Kol, K., Ebisch, R., Piek, J., Beugeling, M., Vergeldt, T., & Bekkers, R. (2021). Adjuvant Hysterectomy for Cervical Cancer Patients Treated with Chemoradiation Therapy: A Systematic Review on the Pathology-Proven Residual Disease Rate. Cancers, 13(24), . https://doi.org/10.3390/cancers13246190
van Kol, Kim, et al. "Adjuvant Hysterectomy for Cervical Cancer Patients Treated with Chemoradiation Therapy: A Systematic Review on the Pathology-Proven Residual Disease Rate." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246190
van Kol K, Ebisch R, Piek J, Beugeling M, Vergeldt T, Bekkers R. Adjuvant Hysterectomy for Cervical Cancer Patients Treated with Chemoradiation Therapy: A Systematic Review on the Pathology-Proven Residual Disease Rate. Cancers (Basel). 2021 Dec 08;13(24). doi: 10.3390/cancers13246190. PMID: 34944810.
Copy Download .nbib Format: NLM
Understanding VA's Use of and Relationships With Community Care Providers Under the MISSION Act.

Medical care

Mattocks KM, Kroll-Desrosiers A, Kinney R, Elwy AR, Cunningham KJ, Mengeling MA.
PMID: 33976074
Med Care. 2021 Jun 01;59:S252-S258. doi: 10.1097/MLR.0000000000001545.

BACKGROUND: Congress has enacted 2 major pieces of legislation to improve access to care for Veterans within the Department of Veterans Affairs (VA). As a result, the VA has undergone a major transformation in the way that care is...

Cite
Mattocks KM, Kroll-Desrosiers A, Kinney R, et al. Understanding VA's Use of and Relationships With Community Care Providers Under the MISSION Act. Med Care. 2021;59:S252-S258doi: 10.1097/MLR.0000000000001545.
Mattocks, K. M., Kroll-Desrosiers, A., Kinney, R., Elwy, A. R., Cunningham, K. J., & Mengeling, M. A. (2021). Understanding VA's Use of and Relationships With Community Care Providers Under the MISSION Act. Medical care, 59S252-S258. https://doi.org/10.1097/MLR.0000000000001545
Mattocks, Kristin M, et al. "Understanding VA's Use of and Relationships With Community Care Providers Under the MISSION Act." Medical care vol. 59 (2021): S252-S258. doi: https://doi.org/10.1097/MLR.0000000000001545
Mattocks KM, Kroll-Desrosiers A, Kinney R, Elwy AR, Cunningham KJ, Mengeling MA. Understanding VA's Use of and Relationships With Community Care Providers Under the MISSION Act. Med Care. 2021 Jun 01;59:S252-S258. doi: 10.1097/MLR.0000000000001545. PMID: 33976074; PMCID: PMC8132889.
Copy Download .nbib Format: NLM
Hospital admission risk stratification of patients with gout presenting to the emergency department.

Clinical rheumatology

Han W, Allameen NA, Ibrahim I, Dhanasekaran P, Mengling F, Lahiri M.
PMID: 34973076
Clin Rheumatol. 2022 Jan 01; doi: 10.1007/s10067-021-05902-5. Epub 2022 Jan 01.

To characterise gout patients at high risk of hospitalisation and to develop a web-based prognostic model to predict the likelihood of gout-related hospital admissions. This was a retrospective single-centre study of 1417 patients presenting to the emergency department (ED)...

Cite
Han W, Allameen NA, Ibrahim I, et al. Hospital admission risk stratification of patients with gout presenting to the emergency department. Clin Rheumatol. 2022;doi: 10.1007/s10067-021-05902-5.
Han, W., Allameen, N. A., Ibrahim, I., Dhanasekaran, P., Mengling, F., & Lahiri, M. (2022). Hospital admission risk stratification of patients with gout presenting to the emergency department. Clinical rheumatology, . https://doi.org/10.1007/s10067-021-05902-5
Han, Wang, et al. "Hospital admission risk stratification of patients with gout presenting to the emergency department." Clinical rheumatology vol. (2022). doi: https://doi.org/10.1007/s10067-021-05902-5
Han W, Allameen NA, Ibrahim I, Dhanasekaran P, Mengling F, Lahiri M. Hospital admission risk stratification of patients with gout presenting to the emergency department. Clin Rheumatol. 2022 Jan 01; doi: 10.1007/s10067-021-05902-5. Epub 2022 Jan 01. PMID: 34973076.
Copy Download .nbib Format: NLM
The Transcriptional Network That Controls Growth Arrest and Macrophage Differentiation in the Human Myeloid Leukemia Cell Line THP-1.

Frontiers in cell and developmental biology

Gažová I, Lefevre L, Bush SJ, Clohisey S, Arner E, de Hoon M, Severin J, van Duin L, Andersson R, Lengeling A, Hume DA, Summers KM.
PMID: 32719792
Front Cell Dev Biol. 2020 Jul 03;8:498. doi: 10.3389/fcell.2020.00498. eCollection 2020.

The response of the human acute myeloid leukemia cell line THP-1 to phorbol esters has been widely studied to test candidate leukemia therapies and as a model of cell cycle arrest and monocyte-macrophage differentiation. Here we have employed Cap...

Cite
Gažová I, Lefevre L, Bush SJ, et al. The Transcriptional Network That Controls Growth Arrest and Macrophage Differentiation in the Human Myeloid Leukemia Cell Line THP-1. Front Cell Dev Biol. 2020;8:498doi: 10.3389/fcell.2020.00498.
Gažová, I., Lefevre, L., Bush, S. J., Clohisey, S., Arner, E., de Hoon, M., Severin, J., van Duin, L., Andersson, R., Lengeling, A., Hume, D. A., & Summers, K. M. (2020). The Transcriptional Network That Controls Growth Arrest and Macrophage Differentiation in the Human Myeloid Leukemia Cell Line THP-1. Frontiers in cell and developmental biology, 8498. https://doi.org/10.3389/fcell.2020.00498
Gažová, Iveta, et al. "The Transcriptional Network That Controls Growth Arrest and Macrophage Differentiation in the Human Myeloid Leukemia Cell Line THP-1." Frontiers in cell and developmental biology vol. 8 (2020): 498. doi: https://doi.org/10.3389/fcell.2020.00498
Gažová I, Lefevre L, Bush SJ, Clohisey S, Arner E, de Hoon M, Severin J, van Duin L, Andersson R, Lengeling A, Hume DA, Summers KM. The Transcriptional Network That Controls Growth Arrest and Macrophage Differentiation in the Human Myeloid Leukemia Cell Line THP-1. Front Cell Dev Biol. 2020 Jul 03;8:498. doi: 10.3389/fcell.2020.00498. eCollection 2020. PMID: 32719792; PMCID: PMC7347797.
Copy Download .nbib Format: NLM
Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process.

Pharmaceutics

Gareb B, Posthumus S, Beugeling M, Koopmans P, Touw DJ, Dijkstra G, Kosterink JGW, Frijlink HW.
PMID: 31450748
Pharmaceutics. 2019 Aug 23;11(9). doi: 10.3390/pharmaceutics11090428.

Infliximab (IFX) is an intravenously administered monoclonal antibody antagonizing the effects of tumor necrosis factor-alpha (TNF) systemically and is efficacious in the treatment of inflammatory bowel disease (IBD). However, studies suggest that the anti-inflammatory effects result from local immunomodulation...

Cite
Gareb B, Posthumus S, Beugeling M, et al. Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. Pharmaceutics. 2019;11(9)doi: 10.3390/pharmaceutics11090428.
Gareb, B., Posthumus, S., Beugeling, M., Koopmans, P., Touw, D. J., Dijkstra, G., Kosterink, J. G. W., & Frijlink, H. W. (2019). Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. Pharmaceutics, 11(9), . https://doi.org/10.3390/pharmaceutics11090428
Gareb, Bahez, et al. "Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process." Pharmaceutics vol. 11,9 (2019). doi: https://doi.org/10.3390/pharmaceutics11090428
Gareb B, Posthumus S, Beugeling M, Koopmans P, Touw DJ, Dijkstra G, Kosterink JGW, Frijlink HW. Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. Pharmaceutics. 2019 Aug 23;11(9). doi: 10.3390/pharmaceutics11090428. PMID: 31450748; PMCID: PMC6781063.
Copy Download .nbib Format: NLM
Volumetric Regression in Brain Metastases After Stereotactic Radiotherapy: Time Course, Predictors, and Significance.

Frontiers in oncology

Oft D, Schmidt MA, Weissmann T, Roesch J, Mengling V, Masitho S, Bert C, Lettmaier S, Frey B, Distel LV, Fietkau R, Putz F.
PMID: 33489888
Front Oncol. 2021 Jan 08;10:590980. doi: 10.3389/fonc.2020.590980. eCollection 2020.

BACKGROUND: There is insufficient understanding of the natural course of volumetric regression in brain metastases after stereotactic radiotherapy (SRT) and optimal volumetric criteria for the assessment of response and progression in radiotherapy clinical trials for brain metastases are currently...

Cite
Oft D, Schmidt MA, Weissmann T, et al. Volumetric Regression in Brain Metastases After Stereotactic Radiotherapy: Time Course, Predictors, and Significance. Front Oncol. 2021;10:590980doi: 10.3389/fonc.2020.590980.
Oft, D., Schmidt, M. A., Weissmann, T., Roesch, J., Mengling, V., Masitho, S., Bert, C., Lettmaier, S., Frey, B., Distel, L. V., Fietkau, R., & Putz, F. (2020). Volumetric Regression in Brain Metastases After Stereotactic Radiotherapy: Time Course, Predictors, and Significance. Frontiers in oncology, 10590980. https://doi.org/10.3389/fonc.2020.590980
Oft, Dominik, et al. "Volumetric Regression in Brain Metastases After Stereotactic Radiotherapy: Time Course, Predictors, and Significance." Frontiers in oncology vol. 10 (2020): 590980. doi: https://doi.org/10.3389/fonc.2020.590980
Oft D, Schmidt MA, Weissmann T, Roesch J, Mengling V, Masitho S, Bert C, Lettmaier S, Frey B, Distel LV, Fietkau R, Putz F. Volumetric Regression in Brain Metastases After Stereotactic Radiotherapy: Time Course, Predictors, and Significance. Front Oncol. 2021 Jan 08;10:590980. doi: 10.3389/fonc.2020.590980. eCollection 2020. PMID: 33489888; PMCID: PMC7820888.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 38 entries